ReviewFrontiers in neurology2025
Current perspectives on the early identification and management of delirium after acute stroke reperfusion therapy.
Review in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Delirium is a common and severe complication following acute cerebral ischemic stroke reperfusion, affecting cognitive and motor recovery and associated with poor long-term outcomes, prolonged hospitalization, increased readmission, and higher mortality. Identifying risk factors, understanding the pathogenesis (especially reperfusion injury), and implementing early intervention are crucial. However, the complex etiology and limited efficacy of drug treatments make early detection and management challenging. Recent studies have identified factors such as age, NIHSS score, pre-stroke cognition, and post-reperfusion inflammation, along with biomarkers, as predictors of delirium. Family involvement and environmental optimization may also reduce risk. This review summarizes current evidence on risk factors, pathogenesis, biomarkers, and interventions to improve early identification, reduce disability, and improve prognosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.